Trial No. Principal Investigator Trial Name
BMS CA209-274 Babu A phase 3 randomized, double-blind, multi-center study of adjuvant Nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma
TRIO-US LILLY 14T-MC-JVDC Babu A phase 3, randomized, double-blind placebo-controlled study of Ramucirumab plus Docetaxel versus placebo plus Docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma who progressed on or after platinum-based therapy